Navigation Links
Androgen Production Continues in Prostate Cancer Tumors
Date:6/3/2008

Growths are able to maintain significant testosterone levels despite therapy, study finds

TUESDAY, June 3 (HealthDay News) -- U.S. researchers have uncovered new information about how metastatic prostate cancer becomes resistant to androgen-deprivation therapy, which suppresses circulating testosterone, the hormone that promotes prostate cancer growth.

Androgen therapy, which involves the use of surgical castration or medical castration with testosterone-blocking drugs, does extend survival time for patients, but it isn't a cure. Eventually, the cancer becomes resistant to androgen deprivation and continues to grow.

"We found that despite the suppression of circulating androgen levels to very low or castrate levels, metastatic prostate tumors are themselves able to maintain significant levels of testosterone, which fuels the growth of the cancer," Dr. Elahe Mostaghel, a clinical research association at Seattle's Fred Hutchinson Cancer Research Center, said in a prepared statement.

Mostaghel and colleagues found that testosterone levels in metastatic prostate tumors (cancer that's spread from the prostate to other parts of the body) from castrate men who'd just died were four times higher than in benign and cancerous prostate tissue in men with normal circulating androgen levels.

They also discovered that metastatic prostate tumor tissue contains the genetic information needed to make the proteins that produce testosterone and other androgen hormones.

"We not only found that metastatic tumor tissues have high enough androgen levels within them to support continued growth of the tumor cells, but also a critically important reason behind why those androgens are there -- the discovery that the gene pathways for synthesizing androgens from cholesterol appear to be present in the distant tumor sites. This finding will allow us to start honing in on the specific source of those androgens and how we can eliminate them," Mostaghel said.

"As we develop new drug targets, we will need to focus on enzymes that seem to be active in the tumor itself. This offers a new way of looking at hormone suppression. In addition to systemic suppression, it suggests we also need to target hormone suppression much more specifically, inside the tumor itself."

The study was published in the June 1 issue of Cancer Research.

More information

The National Cancer Institute has more about prostate cancer treatment.



-- Robert Preidt



SOURCE: Fred Hutchinson Cancer Research Center, news release, June 1, 2008


'/>"/>
Copyright©2008 ScoutNews,LLC.
All rights reserved

Related medicine news :

1. How advanced prostate cancer becomes resistant to androgen-deprivation therapy
2. Pharmacopeia Acquires Selective Androgen Receptor Modulator (SARM) Program from Bristol-Myers Squibb
3. Golden Rainbow Takes a Musical Journey for Its 22nd Annual Ribbon of Life Production Show
4. JMR Electronics BlueStor(TM) Storage Array Empowers HoneySheds Post Production Process
5. Dutch Authorize Manufacture of Vaccinogens New Cancer Vaccine; License Clears Path to European Production, Final FDA Trial
6. Epitomics receives ISO 9001 certification for the production of Rabbit Monoclonal Antibodies.
7. Pfizer Partners with REvolution Computing to Improve Medicine Production Pipeline
8. Vystar Corporation and Revertex Malaysia Sign Vytex(TM) NRL Production Contract
9. Disturbed regulation of insulin production
10. European Society of Human Reproduction & Embryology 24th annual meeting
11. Worlds Lightest, Rigid, Folding Frame Wheelchair now in Production
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2017)... ... 23, 2017 , ... Moisture measurement is a necessary process ... paramount to success. Selecting an inappropriate measurement method can cause costly errors, and ... same equipment. Rare or expensive substances are wasted and production may even be ...
(Date:1/23/2017)... ... 2017 , ... "ProRandom is a set of camera tools that allow video editors to integrate ... Pro X," said Christina Austin - CEO of Pixel Film Studios. , With ProRandom, ... video footage. ProRandom works by using a virtual camera to create the illusion of ...
(Date:1/23/2017)... , ... January 23, 2017 ... ... Foundation (OREF), in partnership with the American Society of Anesthesiologists® (ASA®), the ... (APSF), the American Academy of Orthopaedic Surgeons (AAOS) and the Cigna Foundation, ...
(Date:1/23/2017)... ... ... Inn at the Mill”: a story of love and redemption, hope and uncertainty as ... content. , “The Inn at the Mill” is the creation of published author, Lois ... is now living in Berks County on Crow Hill. The inn, the mill ...
(Date:1/23/2017)... ... January 23, 2017 , ... ... and resources at seafoodnutrition.org/programs and seafoodnutrition.org/resources to assist in teaching communities and ... resources have been developed for use by nutrition educators and influencers within ...
Breaking Medicine News(10 mins):
(Date:1/23/2017)... 23, 2017 Varias proteínas ... enal) y el riesgo de diálisis ... pabetalone    Resverlogix Corp. ("Resverlogix" o ... de un ensayo en fase 1 con sede en ... (renal) severa. Los datos demostraron unos resultados importantes en ...
(Date:1/23/2017)... , January 23, 2017 A new Transparency ... Market was valued at US$0.53 bn in 2013 and is ... strong 17.50% CAGR between 2014 and 2022. The title of the ... Size, Volume, Share, Growth, Trends and Forecast 2014 - 2022." ... Non-invasive prenatal testing (NIPT), ...
(Date:1/23/2017)... 2017  ResMed (NYSE : RMD), BMC (Pékin, Chine) et ... aujourd,hui qu,ils se sont mis d,accord sur le règlement ... BMC et 3B seront autorisés à vendre leurs produits ... et ResMed effectuera le paiement de la décision en ... de Floride entre les deux parties. Le règlement n,inclut ...
Breaking Medicine Technology: